61 results on '"Andersson FL"'
Search Results
2. Patients’ Preferences Related to Treatments for Endometriosis-Related Pain: Results of a Discrete Choice Experiment in the UK
- Author
-
Germain, N, primary, Aballéa, S, additional, Andersson, FL, additional, Korchagina, D, additional, Hawken, NA, additional, and Toumi, M, additional
- Published
- 2017
- Full Text
- View/download PDF
3. Cost of Illness Analysis of Nocturia in Germany, Sweden, and the United Kingdom
- Author
-
Weidlich, D, primary, Andersson, FL, additional, and Guest, J, additional
- Published
- 2016
- Full Text
- View/download PDF
4. Impact Of Nocturia On Quality Of Life – Mapping Of Sf-12 To Utility Values Using Clinical Trial Data
- Author
-
Lee, D, primary, Nielsen, SK, additional, Kidd, R, additional, and Andersson, FL, additional
- Published
- 2015
- Full Text
- View/download PDF
5. Hrqol And Utility In Nocturia Are Correlated To Number Of Voids
- Author
-
Andersson, FL, primary, Juul, KV, additional, Raymond, K, additional, and Rosen, RC, additional
- Published
- 2015
- Full Text
- View/download PDF
6. Nocturia Work Productivity And Activity Impairment Compared To Other Common Chronic Diseases: A Systematic Review
- Author
-
Miller, PS, primary and Andersson, FL, additional
- Published
- 2015
- Full Text
- View/download PDF
7. Costs Of Septic Shock In England, Wales And Northern Ireland In 2012
- Author
-
Andersson, FL, primary, Palencia, R, additional, and Kjølbye, AL, additional
- Published
- 2015
- Full Text
- View/download PDF
8. Delay Of Optimal Nocturia Treatment Is Costly: Results Of A Real World Survey Of Patients In Europe And The Usa
- Author
-
Andersson, FL, primary, Anderson, P, additional, Juul, KV, additional, Wood, R, additional, Piercy, J, additional, and Weiss, JP, additional
- Published
- 2015
- Full Text
- View/download PDF
9. PUK16 - Assessing Sleep Impact in Patients with Nocturia Disorder
- Author
-
DeMuro, C, Lewis, S, Barrett, A, and Andersson, FL
- Published
- 2018
- Full Text
- View/download PDF
10. PIH21 - Patients’ Preferences Related to Treatments for Endometriosis-Related Pain: Results of a Discrete Choice Experiment in the UK
- Author
-
Germain, N, Aballéa, S, Andersson, FL, Korchagina, D, Hawken, NA, and Toumi, M
- Published
- 2017
- Full Text
- View/download PDF
11. PUK9 - Cost of Illness Analysis of Nocturia in Germany, Sweden, and the United Kingdom
- Author
-
Weidlich, D, Andersson, FL, and Guest, J
- Published
- 2016
- Full Text
- View/download PDF
12. PHP90 - Costs Of Septic Shock In England, Wales And Northern Ireland In 2012
- Author
-
Andersson, FL, Palencia, R, and Kjølbye, AL
- Published
- 2015
- Full Text
- View/download PDF
13. PUK27 - Nocturia Work Productivity And Activity Impairment Compared To Other Common Chronic Diseases: A Systematic Review
- Author
-
Miller, PS and Andersson, FL
- Published
- 2015
- Full Text
- View/download PDF
14. PUK22 - Hrqol And Utility In Nocturia Are Correlated To Number Of Voids
- Author
-
Andersson, FL, Juul, KV, Raymond, K, and Rosen, RC
- Published
- 2015
- Full Text
- View/download PDF
15. PUK21 - Impact Of Nocturia On Quality Of Life – Mapping Of Sf-12 To Utility Values Using Clinical Trial Data
- Author
-
Lee, D, Nielsen, SK, Kidd, R, and Andersson, FL
- Published
- 2015
- Full Text
- View/download PDF
16. PUK20 - Delay Of Optimal Nocturia Treatment Is Costly: Results Of A Real World Survey Of Patients In Europe And The Usa
- Author
-
Andersson, FL, Anderson, P, Juul, KV, Wood, R, Piercy, J, and Weiss, JP
- Published
- 2015
- Full Text
- View/download PDF
17. PUK27 Nocturia Work Productivity And Activity Impairment Compared To Other Common Chronic Diseases: A Systematic Review
- Author
-
Miller, PS and Andersson, FL
- Subjects
urologic and male genital diseases ,female genital diseases and pregnancy complications - Full Text
- View/download PDF
18. PUK22 Hrqol And Utility In Nocturia Are Correlated To Number Of Voids
- Author
-
Andersson, FL, Juul, KV, Raymond, K, and Rosen, RC
- Full Text
- View/download PDF
19. PUK20 Delay Of Optimal Nocturia Treatment Is Costly: Results Of A Real World Survey Of Patients In Europe And The Usa
- Author
-
Andersson, FL, Anderson, P, Juul, KV, Wood, R, Piercy, J, and Weiss, JP
- Full Text
- View/download PDF
20. PHP90 Costs Of Septic Shock In England, Wales And Northern Ireland In 2012
- Author
-
Andersson, FL, Palencia, R, and Kjølbye, AL
- Full Text
- View/download PDF
21. Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: the RECUR Germany study.
- Author
-
Antunes A, Tricotel A, Wilk A, Dombrowski S, Rinta-Kokko H, Andersson FL, and Ghosh S
- Subjects
- Humans, Germany epidemiology, Male, Female, Aged, Middle Aged, Retrospective Studies, Longitudinal Studies, Adult, Aged, 80 and over, Clostridioides difficile, Clostridium Infections mortality, Clostridium Infections economics, Clostridium Infections microbiology, Clostridium Infections epidemiology, Cost of Illness, Recurrence, Health Care Costs statistics & numerical data
- Abstract
Background: Clostridioides difficile infections (CDIs) and recurrences (rCDIs) remain a major public health challenge due to substantial mortality and associated costs. This study aims to generate real-world evidence on the mortality and economic burden of CDI in Germany using claims data between 2015 and 2019., Methods: A longitudinal and matched cohort study using retrospective data from Statutory Health Insurance (SHI) was conducted in Germany with the BKK database. Adults diagnosed with CDI in hospital and community settings between 2015 and 2018 were included in the study. Patients had a minimum follow-up of 12-months. All-cause mortality was described at 6-, 12-, and 24-months. Healthcare resource usage (HCRU) and associated costs were assessed at 12-months of follow-up. A cohort of non-CDI patients matched by demographic and clinical characteristics was used to assess excess mortality and incremental costs of HCRU. Up to three non-CDI patients were matched to each CDI patient., Results: A total of 9,977 CDI patients were included in the longitudinal cohort. All-cause mortality was 32%, 39% and 48% at 6-, 12-, and 24-months, respectively, with minor variations by number of rCDIs. When comparing matched CDI (n = 5,618) and non-CDI patients (n = 16,845), CDI patients had an excess mortality of 2.17, 1.35, and 0.94 deaths per 100 patient-months, respectively. HCRU and associated costs were consistently higher in CDI patients compared to non-CDI patients and increased with recurrences. Total mean and median HCRU cost per patient during follow-up was €12,893.56 and €6,050 in CDI patients, respectively, with hospitalisations representing the highest proportion of costs. A total mean incremental cost per patient of €4,101 was estimated in CDI patients compared to non-CDI patients, increasing to €13,291 in patients with ≥ 3 rCDIs., Conclusions: In this real-world study conducted in Germany, CDI was associated with increased risk of death and substantial costs to health systems due to higher HCRU, especially hospitalisations. HCRU and associated costs were exacerbated by rCDIs., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
22. Clostridioides difficile infection, recurrence and the associated healthcare consumption in Sweden between 2006 and 2019: a population-based cohort study.
- Author
-
Boven A, Simin J, Andersson FL, Vlieghe E, Callens S, Zeebari Z, Engstrand L, and Brusselaers N
- Subjects
- Humans, Female, Male, Sweden epidemiology, Middle Aged, Aged, Adult, Cohort Studies, Young Adult, Adolescent, Aged, 80 and over, Clostridioides difficile, Hospitalization statistics & numerical data, Length of Stay statistics & numerical data, Cross Infection epidemiology, Incidence, Child, Child, Preschool, Infant, Patient Acceptance of Health Care statistics & numerical data, Clostridium Infections epidemiology, Recurrence
- Abstract
Background: Clostridioides difficile infection (CDI) causes a major burden to individuals and society, yet the impact may vary depending on age, sex, underlying comorbidities and where CDI was acquired (hospital or community)., Methods: This Swedish nationwide population-based cohort study (2006-2019) compared all 43,150 individuals with CDI to their 355,172 matched controls (first year and entire follow-up). Negative binomial regression models compared the cumulated length of stay, number of in-hospital admissions, outpatient visits and prescriptions after the first CDI episode expressed as incidence rate ratios (IRR) and 95% confidence intervals for the entire follow-up., Results: Overall, 91.6% of CDI cases were hospital acquired, and 16.8% presented with recurrence(s); 74.8%of cases were ≥ 65 years and 54.2% were women. Compared to individuals without CDI, in-hospital stay rates were 18.01 times higher after CDI (95% CI 17.40-18.63, first-year: 27.4 versus 1.6 days), 9.45 times higher in-hospital admission (95% CI 9.16-9.76, first-year: 2.6 versus 1.3 hospitalisations), 3.94 times higher outpatient visit (95% CI 3.84-4.05, first-year: 4.0 versus 1.9 visits) and 3.39 times higher dispensed prescriptions rates (95% CI 3.31-3.48, first-year: 25.5 versus 13.7 prescriptions). For all outcomes, relative risks were higher among the younger (< 65 years) than the older (≥ 65 years), and in those with fewer comorbidities, but similar between sexes. Compared to those without recurrence, individuals with recurrence particularly showed a higher rate of hospital admissions (IRR = 1.18, 95% 1.12-1.24). Compared to community-acquired CDI, those with hospital-acquired CDI presented with a higher rate of hospital admissions (IRR = 7.29, 95% CI 6.68-7.96) and a longer length of stay (IRR = 7.64, 95% CI 7.07-8.26)., Conclusion: CDI was associated with increased health consumption in all affected patient groups. The majority of the CDI burden could be contributed to hospital-acquired CDI (~ 9/10), older patients (~ 3/4) and those with multiple comorbidities (~ 6/10 Charlson score ≥ 3), with 1/5 of the total CDI burden contributed to individuals with recurrence. Yet, relatively speaking the burden was higher among the younger and those with fewer comorbidities, compared to their peers without CDI., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
23. Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: The RECUR England study.
- Author
-
Ghosh S, Antunes A, Rinta-Kokko H, Chaparova E, Lay-Flurrie S, Tricotel A, and Andersson FL
- Subjects
- Humans, Retrospective Studies, Cohort Studies, Financial Stress, England epidemiology, Recurrence, Clostridioides difficile, Clostridium Infections
- Abstract
Objectives: To generate real-world evidence on all-cause mortality and economic burden of Clostridioides difficile infections (CDIs) and recurrences (rCDIs) in England., Methods: We conducted a cohort study using retrospective data from Clinical Practice Research Datalink linked to Hospital Episode Statistics. Patients diagnosed with CDI in hospital and community settings during 2015-2018 were included and followed for ≥1 year. All-cause mortality was described at 6, 12, and 24 months. Healthcare resource usage (HCRU) and associated costs were assessed at 12 months of follow-up. A cohort of non-CDI patients, matched by demographic and clinical characteristics including Charlson Comorbidity Index score, was used to assess excess mortality and incremental costs of HCRU., Results: All-cause mortality among CDI patients at 6, 12, and 24 months was 15.87%, 20.37%, and 27.03%, respectively. A higher proportion of rCDI patients died at any point during follow-up. Compared with matched non-CDI patients, excess mortality was highest at 6 months with 1.81 and 2.53 deaths per 100 patient-months among CDI and ≥1 rCDI patients. Hospitalizations were the main drivers of costs, with an incremental cost of £1209.21 per CDI patient. HCRU and costs increased with rCDIs., Conclusion: CDI poses a substantial mortality and economic burden, further amplified by rCDIs., Competing Interests: Declarations of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: FLA was, at the time of the study, employed by Ferring Pharmaceuticals A/S. AA, HRK, SL-F, EC, and AT are employed by IQVIA. SG is a member of steering committees for Janssen, Bristol Myers Squibb, and Abbvie; participates in drug monitoring committees for Janssen; has speaker commitments for Abbvie, Takeda, Janssen, Pfizer, Gilead, Galapagos, Ferring Pharmaceuticals A/S, Eli-Lilly, and Celltrion; and is a member of advisory committees for Janssen, Abbvie, Takeda, Gilead, Galapagos, Eli-Lilly, Pfizer, Celltrion, and Ferring Pharmaceuticals A/S., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
24. Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015 - 2019: the RECUR Germany study.
- Author
-
Tricotel A, Antunes A, Wilk A, Dombrowski S, Rinta-Kokko H, Andersson FL, and Ghosh S
- Subjects
- Adult, Humans, Anti-Bacterial Agents therapeutic use, Retrospective Studies, Risk Factors, Recurrence, Clostridioides difficile, Clostridium Infections epidemiology, Clostridium Infections drug therapy, Sepsis epidemiology, Sepsis drug therapy
- Abstract
Background: This real-world study assessed the epidemiology and clinical complications of Clostridioides difficile infections (CDIs) and recurrences (rCDIs) in hospital and community settings in Germany from 2015 - 2019., Methods: An observational retrospective cohort study was conducted among adult patients diagnosed with CDI in hospital and community settings using statutory health insurance claims data from the BKK database. A cross-sectional approach was used to estimate the annual incidence rate of CDI and rCDI episodes per 100,000 insurants. Patients' demographic and clinical characteristics were described at the time of first CDI episode. Kaplan-Meier method was used to estimate the time to rCDIs and time to complications (colonic perforation, colectomy, loop ileostomy, toxic megacolon, ulcerative colitis, peritonitis, and sepsis). A Cox model was used to assess the risk of developing complications, with the number of rCDIs as a time-dependent covariate., Results: A total of 15,402 CDI episodes were recorded among 11,884 patients. The overall incidence of CDI episodes declined by 38% from 2015 to 2019. Most patients (77%) were aged ≥ 65 years. Around 19% of CDI patients experienced at least one rCDI. The median time between index CDI episode to a rCDI was 20 days. The most frequent complication within 12-months of follow-up after the index CDI episode was sepsis (7.57%), followed by colectomy (3.20%). The rate of complications increased with the number of rCDIs. The risk of any complication increased by 31% with each subsequent rCDI (adjusted hazard ratio [HR]: 1.31, 95% confidence interval: 1.17;1.46)., Conclusions: CDI remains a public health concern in Germany despite a decline in the incidence over recent years. A substantial proportion of CDI patients experience rCDIs, which increase the risk of severe clinical complications. The results highlight an increasing need of improved therapeutic management of CDI, particularly efforts to prevent rCDI., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
25. The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence.
- Author
-
Moreels N, Boven A, Gressani O, Andersson FL, Vlieghe E, Callens S, Engstrand L, Simin J, and Brusselaers N
- Subjects
- Humans, Anti-Bacterial Agents adverse effects, Proton Pump Inhibitors adverse effects, Streptogramins, Clostridium Infections epidemiology, Quinolones
- Abstract
Background: Antibiotics and proton pump inhibitors (PPI) are recognized risk factors for acquisition and recurrence of Clostridioides difficile infection (CDI), yet combined effects remain unclear., Objectives: To assess the short- and long-term effects of antibiotics and PPIs on CDI risk and recurrence., Methods: Population-based study including all 43 152 patients diagnosed with CDI in Sweden (2006-2019), and 355 172 matched population controls without CDI. The impact of antibiotics and PPIs on CDI risk and recurrence was explored for recent (0-30 days) and preceding (31-180 days) use prior to their first CDI diagnosis, using multivariable conditional logistic regression presented as odds ratios (ORs) and 95% confidence interval, adjusted for demographics, comorbidities and other drugs., Results: Compared to controls, the combined effect of recent PPIs and antibiotics [ORAB+PPI = 17.51 (17.48-17.53)] on CDI risk was stronger than the individual effects [ORAB = 15.37 (14.83-15.93); ORPPI = 2.65 (2.54-2.76)]. Results were less pronounced for exposure during the preceding months. Dose-response analyses showed increasing exposure correlated with CDI risk [recent use: ORAB = 6.32 (6.15-6.49); ORPPI = 1.65 (1.62-1.68) per prescription increase].Compared to individuals without recurrence (rCDI), recent [ORAB = 1.30 (1.23-1.38)] and preceding [ORAB = 1.23 (1.16-1.31); ORPPI = 1.12 (1.03-1.21)] use also affected the risk of recurrence yet without significant interaction between both. Recent macrolides/lincosamides/streptogramins; other antibacterials including nitroimidazole derivates; non-penicillin beta lactams and quinolones showed the strongest association with CDI risk and recurrence, particularly for recent use. PPI use, both recent and preceding, further increased the CDI risk associated with almost all antibiotic classes., Conclusion: Recent and less recent use of PPIs and systemic antibiotics was associated with an increased risk of CDI, particularly in combination., (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.)
- Published
- 2024
- Full Text
- View/download PDF
26. Clostridioides difficile infections, recurrences, and clinical outcomes in real-world settings from 2015 to 2019: The RECUR England study.
- Author
-
Ghosh S, Antunes A, Rinta-Kokko H, Chaparova E, Lay-Flurrie S, Tricotel A, and Andersson FL
- Subjects
- Adult, Humans, Female, Male, Retrospective Studies, Anti-Bacterial Agents therapeutic use, Risk Factors, Recurrence, Clostridioides difficile, Clostridium Infections drug therapy, Clostridium Infections epidemiology
- Abstract
Objective: To estimate the epidemiological and clinical burden of Clostridioides difficile infections (CDIs) and recurrences (rCDIs) in England., Methods: This retrospective study included adult patients diagnosed with CDI (community or hospital settings) over 2015-2019 from Clinical Practice Research Datalink and Hospital Episode Statistics databases. Incidences of CDI and rCDI were determined annually. Time to subsequent rCDI was estimated by Kaplan-Meier method. Rates of complications were assessed within 12 months from index episode. Association of risk factors with complications was evaluated using a Cox regression model., Results: A total of 52,443 CDI episodes were recorded among 36,913 patients. Of these, 75% were aged ≥65 years, 59% were women; 73% were treated in community settings. CDI incidence remained stable (111 episodes per 100,000 patients in 2019). Around 21% of patients had ≥1 rCDI. Sepsis (12%) was the most common complication, followed by colectomy and ulcerative colitis. Age, gender, comorbidities, rCDI, preindex medical procedures, hospitalizations and consultations, and CDI treatment in hospital, were found to increase the risk of complication., Conclusions: CDI remains a concern in England. The study highlights the importance of managing primary and rCDI episodes via effective and improved therapies to prevent fatal complications., Competing Interests: Declarations of competing interest FLA was, at the time of the study, employed by Ferring Pharmaceuticals A/S. HRK was at the time of the study employed by IQVIA. AA, SL-F, EC, AT are employed by IQVIA. SG is a member of steering committees for Janssen, Bristol Myers Squibb and Abbvie, participates in drug monitoring committees for Janssen, has speaker commitments for Abbvie, Takeda, Janssen, Pfizer, Gilead, Galapagos, Ferring Pharmaceuticals A/S, Eli-Lilly, Celltrion, and is a member of advisory committees for Janssen, Abbvie, Takeda, Gilead, Galapagos, Eli-Lilly, Pfizer, Celltrion, and Ferring Pharmaceuticals A/S., (Copyright © 2024. Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
27. Clostridioides difficile infection-associated cause-specific and all-cause mortality: a population-based cohort study.
- Author
-
Boven A, Vlieghe E, Engstrand L, Andersson FL, Callens S, Simin J, and Brusselaers N
- Subjects
- Humans, Female, Male, Aged, Sweden epidemiology, Middle Aged, Adult, Aged, 80 and over, Cohort Studies, Young Adult, Cross Infection mortality, Cross Infection epidemiology, Cross Infection microbiology, Adolescent, Comorbidity, Clostridioides difficile, Community-Acquired Infections mortality, Community-Acquired Infections microbiology, Community-Acquired Infections epidemiology, Incidence, Risk Factors, Infant, Child, Preschool, Cause of Death, Child, Clostridium Infections mortality, Clostridium Infections epidemiology, Clostridium Infections microbiology
- Abstract
Objectives: Clostridioides difficile infection (CDI) is a common healthcare-associated infection and leading cause of gastroenteritis-related mortality worldwide. However, data on CDI-associated mortality are scarce. We aimed to examine the association between CDI and all-cause and cause-specific mortality. We additionally explored contributing causes of mortality, including recurrent CDI, hospital- or community-acquired CDI, chronic comorbidities, and age., Methods: This nationwide population-based cohort study (from 2006 to 2019) compared individuals with CDI with the entire Swedish background population using standardized mortality ratios. In addition, a matched-cohort design (1:10), utilizing multivariable Poisson-regression models, provided incidence rate ratios (IRRs) with 95% CIs., Results: This study included 43 150 individuals with CDI and 355 172 controls. In total, 69.7% were ≥65 years, and 54.9% were female. CDI was associated with a 3- to 7-fold increased mortality rate (IRR = 3.5, 95% CI: 3.3-3.6; standardized mortality ratio = 6.8, 95% CI: 6.7-6.9) compared with the matched controls and Swedish background population, respectively. Mortality rates were highest for hospital-acquired CDI (IRR = 2.4, 95% CI: 1.9-3.2) and during the first CDI episode (IRR = 0.2, 95% CI: 0.2-0.3 for recurrent versus first CDI). Individuals with CDI had more chronic comorbidities than controls, yet mortality remained higher among CDI cases even after adjustment and stratification for comorbidity; CDI was associated with increased mortality (IRR = 6.1, 95% CI: 5.5-6.8), particularly among those without any chronic comorbidities., Discussion: CDI was associated with elevated all-cause and cause-specific mortality, despite possible confounding by ill health. Mortality rates were consistently increased across sexes, all age groups, and comorbidity groups., (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
28. Nocturnal polyuria in women: results from the EpiNP study.
- Author
-
Mueller ER, Weiss JP, Bosch JLHR, Chughtai B, Rosenberg MT, Bacci ED, Simeone JC, Andersson FL, Juul K, Coyne KS, and Chapple CR
- Subjects
- Humans, Female, Middle Aged, Polyuria epidemiology, Polyuria diagnosis, Polyuria etiology, Cross-Sectional Studies, Nocturia etiology, Urinary Bladder, Overactive complications, Lower Urinary Tract Symptoms epidemiology, Lower Urinary Tract Symptoms complications
- Abstract
Introduction and Hypothesis: Data from a large US population-based, cross-sectional, epidemiological study (the EpiNP Study) were used to assess the symptoms and bother experienced by women with nocturnal polyuria (NP)., Methods: Consenting participants recruited from an online panel completed the baseline EpiNP survey online (Lower Urinary Tract Symptoms Tool and urological comorbidities). All reporting ≥2 voids/night and a random sample of 100 respondents, each reporting 0 or 1 void/night were asked to complete a 3-day web-based bladder diary recording time, volume, and urgency rating of each void. NP was calculated by the proportion of urine production that occurred during nocturnal hours using a Nocturnal Polyuria Index (NPI33) threshold of >0.33 or nocturnal urine production of >90 ml/h (NUP90). The frequency of participants reporting LUTS and bother was determined by age and NP: idiopathic NP, NP associated with overactive bladder (NPOAB), NP associated with comorbidities (NPCom), and no NP (did not meet NP criteria)., Results: A total of 5,290 women completed the baseline survey. Mean age (range) was 54.9 (30-95) years; 1,841 (34.8%) reported ≥2 nocturnal voids. The prevalence of LUTS increased across the lifespan; however, bother associated with each LUTS decreased with increasing age. The percentage of women rating bother by nocturia episodes ≥2 "> somewhat" ranged from 40.3% to 68.3%, with bother ratings highest in the NPOAB and No NP groups., Conclusions: NP is prevalent in women with considerable bother and is often associated with other urinary symptoms. Multifactorial causes and potential treatments of NP should be considered, particularly at a later age., (© 2023. The International Urogynecological Association.)
- Published
- 2023
- Full Text
- View/download PDF
29. Unmet Parenthood Goals, Health-Related Quality of Life and Apparent Irrationality: Understanding the Value of Treatments for Infertility.
- Author
-
Skedgel C, Cubi-Molla P, Mott D, Gameiro S, Boivin J, Al-Janabi H, Brazier J, Markert M, Andersson FL, and Jofre-Bonet M
- Abstract
An increasing number of prospective parents are experiencing infertility along with associated negative impacts on mental health and life satisfaction that can extend across a network of individuals and family members. Assistive reproductive technologies (ART) can help prospective parents achieve their parenthood goals but, like any health technology, they must demonstrate acceptable 'value for money' to qualify for public funding. We argue that current approaches to understanding the value of ART, including quality-adjusted life-year (QALY) gains based on changes in health-related quality of life (HRQOL) and, more often, cost per live birth, are too narrow to capture the full impact of unmet parenthood goals and ART. We see a fundamental disconnect between measures of HRQOL and broader measures of wellbeing associated with met and unmet parenthood goals. We also suggest that simple concepts such as 'patient' and 'carer' are of limited applicability in the context of ART, where 'spillovers' extend across a wide network of individuals, and the person receiving treatment is often not the infertile individual. Consideration of individual and societal wellbeing beyond HRQOL is necessary to understand the full range of negative impacts associated with unmet parenthood goals and the corresponding positive impacts of successful ART. We suggest moving towards a wellbeing perspective on value to achieve a fuller understanding of value and promote cross-sector allocative efficiency., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
30. Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis.
- Author
-
Cortesi PA, Fiorino G, Peyrin-Biroulet L, Mantovani LG, Jairath V, Paridaens K, Andersson FL, and Danese S
- Subjects
- Humans, Cost-Benefit Analysis, State Medicine, Cost-Effectiveness Analysis, Recurrence, Colitis, Ulcerative diagnosis, Colitis, Ulcerative drug therapy
- Abstract
Background: There are no data to assess the value associated with a treat-to-target (T2T) strategy based on tight control of mild-moderate ulcerative colitis (UC)., Aim: To assess the cost-effectiveness of a T2T approach based on the normalisation of clinical signs and faecal calprotectin (FC) METHODS: A decision analytical Markov model was developed to compare T2T algorithm combining clinical symptoms and FC levels to define treatment response and the possible switch to the next treatment line (T2T-FC), and the reference strategy based only on symptoms. The model included five treatment lines and was conducted from the Italian national health service (NHS) perspective using a 3-year time horizon. The model calculated the incremental cost-effectiveness ratio as € per relapse avoided. Deterministic and probabilistic sensitivity analyses were conducted., Results: The cost-effectiveness analysis produced an increased time spent by a patient in clinical remission and FC ≤ 100 level (+0.177 years; about 2 months) and a decreasing number of relapses (-0.1937; -20.9%) per patient using a T2T-FC approach compared to only symptoms. Furthermore, the T2T-FC was associated with higher cost (+€1795). The ICER estimated was €9263 per relapse avoided. These results were confirmed by sensitivity analyses., Conclusions: T2T-FC approach resulted in a higher benefit for mild-moderate UC patients in terms of time in remission and incidence of relapse but was associated with higher costs. Clinical trials and real-world clinical studies are needed to provide additional data on the cost-benefit of this approach., (© 2022 John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
31. The patient burden of nocturnal polyuria in the United States: Results from the epidemiology of nocturnal polyuria (EpiNP) study.
- Author
-
Chapple CR, Rosenberg MT, Mueller ER, Chughtai B, Weiss JP, Juul K, Brooks AB, Bacci ED, Andersson FL, Coyne KS, and Bosch JR
- Subjects
- Male, Humans, Female, United States epidemiology, Middle Aged, Polyuria etiology, Quality of Life, Epidemiologic Studies, Nocturia, Lower Urinary Tract Symptoms epidemiology, Lower Urinary Tract Symptoms complications, Disorders of Excessive Somnolence complications
- Abstract
Objectives: To explore the impact of nocturnal polyuria (NP) on health-related quality of life (HRQoL), work productivity, mental health, fatigue, bother, and daytime sleepiness., Materials and Methods: This large-scale, US population-representative epidemiologic study was conducted in two parts: a web-based survey and 3-day bladder diary. Consenting participants completed the baseline Epidemiology of NP (EpiNP) survey online (Lower Urinary Tract Symptoms [LUTS] Tool, comorbidities, burden, and multiple HRQoL measures). Participants who reported ≥2 voids/night, and a random sample of 100 respondents each reporting 0 or 1 void/night, were sent urine measurement containers and asked to complete the 3-day bladder diary. NP was defined as Nocturnal Polyuria Index >0.33 (NPI33) or nocturnal urine production >90 ml/h (NUP90). Five subgroups were created: Idiopathic NP (NP with no underlying cause), NP associated with symptoms of overactive bladder (NPOAB) or bladder outlet obstruction (NPBOO; men only), NP associated with other comorbidities (NPCOM; e.g., diabetes, hypertension, heart disease, sleep apnea), and no NP (did not meet NP criteria)., Results: A total of 4893 men and 5297 women completed the EpiNP survey; mean age was 54.4 (SD = 14.7). Significantly greater patient burden (p < 0.0001) was evidenced in the nocturia group (≥2 voids/night) versus no nocturia group (0-1 void/night) on daily impact of nocturia, LUTS Bother, prostate symptoms (men only), work productivity, physical and mental health component scores, depression, fatigue, and daytime sleepiness. NP subgroup analyses showed men in the NPBOO group and women in the NPOAB group reported the greatest impact on LUTS bother, fatigue, physical health, work productivity impairment, daytime sleepiness, and depression (women only)., Conclusion: This was the first large-scale, epidemiologic study to explore the impact of different forms of NP on patients' HRQoL. Findings demonstrate that NP associated with other urologic or comorbid conditions appears to have greater patient burden than idiopathic NP, in particular for women., (© 2023 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
32. Partially different? The importance of general equilibrium in health economic evaluations: An application to nocturia.
- Author
-
Hafner M, Yerushalmi E, Andersson FL, and Burtea T
- Subjects
- Humans, Cost-Benefit Analysis, Efficiency, Economics, Medical, Surveys and Questionnaires, Cost of Illness, Nocturia epidemiology
- Abstract
Both the human capital approach and the friction cost approach are frequently used to quantify the productivity costs associated with illness, disability or death in health economic evaluations. In this paper we argue that these approaches have one major, but common shortcoming: they only capture partial equilibrium (PE) effects and therefore underestimate the true potential productivity costs associated with health conditions. They neglect the sizable, indirect, ripple effects in the economy captured by general equilibrium (GE) models. To demonstrate our point, we compare a traditional PE with a GE approach for the application to nocturia, a condition characterized by the need to frequently wake up at night to urinate. Nocturia is associated with substantial impairment of daytime functioning and work productivity. We employ large-scale United Kingdom (UK) employer-employee survey data to estimate the prevalence and productivity loss. These estimates are then used as shared inputs to drive both approaches. We find that the traditional PE approach underestimates the annual productivity cost of clinically relevant nocturia by around 16%. We propose a generalized GE/PE multiplier to approximate the GE effect for other health conditions. Our findings stress the importance of accounting for sizable GE effects when conducting health economic evaluations., (© 2022 The Authors. Health Economics published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
33. Differences in the Prevalence of Nocturnal Polyuria in the U.S. by Definition: Results From the Epidemiology of Nocturnal Polyuria Study. Reply.
- Author
-
Bosch JLHR, Chapple CR, Mueller ER, Rosenberg MT, Chughtai B, Juul K, Coyne KS, Andersson FL, Bacci ED, Simeone JC, and Weiss JP
- Subjects
- Humans, Prevalence, Polyuria epidemiology
- Published
- 2023
- Full Text
- View/download PDF
34. The Prevalence of Nocturnal Polyuria in the United States: Results from the Epidemiology of Nocturnal Polyuria Study.
- Author
-
Weiss JP, Bosch JLHR, Chapple CR, Bacci ED, Simeone JC, Rosenberg MT, Mueller ER, Andersson FL, Juul K, Chughtai B, and Coyne KS
- Subjects
- Middle Aged, Male, Female, Humans, United States epidemiology, Aged, Polyuria etiology, Prevalence, Urination, Nocturia etiology, Lower Urinary Tract Symptoms complications
- Abstract
Background: The prevalence of nocturnal polyuria (NP), which is passing large volumes of urine during the main sleep period, has been investigated primarily in middle-aged to older men. There is thus a gap in the NP evidence base for women and for younger individuals., Objective: To estimate the prevalence of nocturia due to NP in the USA., Design, Setting, and Participants: This large epidemiologic study used a US population-representative sample of men and women aged ≥30 yr to assess the prevalence of NP (NCT04125186)., Outcome Measurements and Statistical Analysis: Consenting participants completed an online survey (Lower Urinary Tract Symptoms Tool and comorbidities). All who reported two or more voids per night and 100 random respondents each reporting no or one void per night were asked to complete a 3-d bladder diary. Two NP definitions were used: nocturnal urine production >90 ml/h (NUP90) and Nocturnal Polyuria Index >0.33 (NPI33). Crude and population-adjusted prevalence results were calculated from completed diaries for the following subgroups by sex and age: idiopathic NP; NP with overactive bladder (NP-OAB) or bladder outlet obstruction (NP-BOO; men only); NP associated with other comorbidities; and no NP (did not meet the NPI33 or NUP90 definition)., Results and Limitations: Among the 10,190 respondents who completed the survey, the mean age was 54.4 yr (range 30-95); 3,339 reported two or more nocturnal voids and 1,763 completed the 3-d diary (response rate 49.3%). The adjusted overall NP prevalence was 31.5% among men and 38.5% among women using the NPI33 definition, and 23.8% among men and 18.1% among women using NUP90. The adjusted idiopathic NP prevalence was lower among men (NPI33: 5.2%; NUP90: 1.4%) than among women (NPI33: 9.8%; NUP90: 4.0%). The prevalence of idiopathic NP decreased with age as NP associated with other possible causes increased with age in men (most common, BOO) and women (most common, OAB)., Conclusions: This is the first population-based study of NP prevalence to include men, women, and young adults. NP is common; a multifactorial etiology should be considered, particularly as age increases., Patient Summary: In this population-based US study, we examined the frequency of nighttime urination among men and women aged ≥30 y and older. We found that nighttime urination is common among men and women. Many conditions can lead to increased nighttime urination as people age., (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
35. Differences in the Prevalence of Nocturnal Polyuria in the U.S. by Definition: Results from the Epidemiology of Nocturnal Polyuria Study.
- Author
-
Bosch JLHR, Chapple CR, Mueller ER, Rosenberg MT, Chughtai B, Juul K, Coyne KS, Andersson FL, Bacci ED, Simeone JC, and Weiss JP
- Subjects
- Adult, Female, Humans, Male, Polyuria etiology, Prevalence, Urination, Nocturia etiology, Urinary Bladder, Overactive diagnosis
- Abstract
Purpose: Prevalence data on nocturnal polyuria (NP), nocturia caused by overproduction of urine during sleep, is primarily limited to men and varies by NP definition. This U.S.-representative epidemiological study of men and women ≥30 years old assessed the prevalence of NP., Materials and Methods: Consenting participants completed the baseline EpiNP (Epidemiology of Nocturnal Polyuria) survey (eg Lower Urinary Tract Symptoms Tool, comorbidities). All reporting ≥2 voids/night and a target of 100 random respondents reporting 0 or 1 void/night were asked to complete 3-day bladder diaries. NP was defined as nocturnal polyuria index (NPI) >0.33 (NPI33) and nocturnal urine production >90 ml/hour (NUP90). Extrapolated prevalence was stratified by sex and subgroups: idiopathic (without underlying causes), associated with overactive bladder (NPOAB), bladder outlet obstruction (NPBOO; men) and comorbidities. Voided volumes and timing, including first uninterrupted sleep period, were assessed by subgroup., Results: A total of 10,190 individuals completed the baseline survey; mean age (range) was 54.4 (30-95). A total of 3,938 individuals were invited to complete the diary; 1,763 (49.3%) completed 3-day bladder diaries. Urine production (maximum nighttime volume, total volume, nocturnal urine production, nocturia index) was higher in both men and women with idiopathic NP and comorbidities. The median number of nighttime voids was greatest for NPBOO in men and NPOAB in women. Bother associated with nighttime voiding differed by NP subgroup but was highest in NPBOO for men (NPI33: 69.6%; NUP90: 71.1%) and NPOAB for women (NPI33: 67.5%; NUP90: 66.0%)., Conclusions: This population-based NP prevalence study including men and women characterizes NP subgroups and provides insights into nocturia treatment by emphasizing factors influencing urine production versus factors influencing bladder capacity.
- Published
- 2022
- Full Text
- View/download PDF
36. Psychometric validation and interpretation of the Nocturia Impact Diary in a clinical trial setting.
- Author
-
Hudgens S, Howerter A, Polek E, and Andersson FL
- Subjects
- Adult, Environment, Humans, Psychometrics, Quality of Life psychology, Reproducibility of Results, Surveys and Questionnaires, Nocturia drug therapy
- Abstract
Purpose: Psychometric evaluation of the Nocturia Impact (NI) Diary was conducted to support its use as a trial endpoint., Methods: As part of a randomized, controlled Phase 2 clinical trial investigating a novel drug candidate for nocturnal polyuria, adult nocturia patients completed the NI Diary and a voiding diary for three nights preceding their clinic visit at Baseline and Weeks 1, 4, 8, and 12 (end of treatment). Exit interviews were conducted to obtain patient impressions of the NI Diary., Results: A total of N = 302 participants were included. Confirmatory factor analysis (CFA) indicated that the 11-item measure is unidimensional with values of CFI, TLI, and RMSEA meeting relevant thresholds. Good internal consistency (Cronbach's α 0.941) and test-retest reliability (intra-class correlation coefficients 0.730-0.880). Convergent validity with two reference measures was demonstrated with strong correlations of 0.573-0.730 were shown. Significant differences (P = 0.0018, standardized effect size = 0.372) between groups defined by number of night-time voids supported known-groups validity. Exit interviews in 66 patients indicated all participants experienced improvement in at least 1 NI Diary item and that a 1-point improvement on the item response scale and 1-void reduction per night (associated with an average best cut point on ROC analysis of - 11.6) constituted meaningful improvement. Anchor and distribution-based analyses identified a meaningful change threshold of - 15 to - 18 points on the NI Diary., Conclusion: The NI Diary is a reliable and valid patient-reported psychometric instrument which is fit-for-purpose to evaluate the impact of nocturia on patient quality of life in the clinical trial setting. Trial registration number and registration date NCT03201419; June 28, 2017., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
37. Cost-effectiveness analysis of carbetocin versus oxytocin for the prevention of postpartum hemorrhage following vaginal birth in the United Kingdom.
- Author
-
Matthijsse S, Andersson FL, Gargano M, and Yip Sonderegger YL
- Subjects
- Cost-Benefit Analysis, Female, Humans, Oxytocin analogs & derivatives, Oxytocin therapeutic use, Pregnancy, State Medicine, United Kingdom, Oxytocics therapeutic use, Postpartum Hemorrhage prevention & control
- Abstract
Aims: To assess the cost-effectiveness of carbetocin versus oxytocin for the prevention of postpartum hemorrhage (PPH) following vaginal birth from the perspective of the UK National Health Service (NHS)., Materials and Methods: A decision tree model was designed to analyze the cost per PPH event avoided associated with utilizing carbetocin versus oxytocin for prophylactic treatment of PPH in women following vaginal birth from a UK perspective. It modelled the potential for women to require an additional uterotonic after prophylaxis, and to still experience a PPH event and receive associated treatment. Inpatient recovery and follow-up periods post-PPH were also included in the model. Costs associated with drug acquisition and administration, PPH management (i.e. additional staffing and possible operating theater and high dependency unit utilization), inpatient hospitalization, and follow-up visits were all considered. Adverse event management costs were not included. Resource utilization varied depending on the severity of the PPH event (as defined by the amount of blood lost). PPH events avoided were estimated. In an exploratory analysis, quality adjusted life years (QALYs) were estimated as well., Results: In the deterministic base case, costs were £55 lower and PPH events were 0.0342 lower per woman with carbetocin use compared to oxytocin use. Across the cohort of 100 women the reduction in PPH events led to the largest cost savings (£4,233 saved) out of all cost categories, with total cost savings of £5,495. Carbetocin utilization amongst the entire cohort led to 3.42 avoided PPH events compared to oxytocin utilization, comprised of 3.03 fewer mild/moderate PPH events and 0.39 fewer severe PPH events. Carbetocin utilization led to 0.0001 additional QALYs per woman., Conclusion: Carbetocin utilization leads to lower prophylactic treatment costs and less PPH events versus oxytocin when utilized for the prevention of PPH following vaginal birth in the UK.
- Published
- 2022
- Full Text
- View/download PDF
38. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.
- Author
-
Finn E, Andersson FL, and Madin-Warburton M
- Subjects
- Clostridium Infections microbiology, Clostridium Infections pathology, Global Health, Humans, Clostridioides difficile isolation & purification, Clostridium Infections epidemiology, Cross Infection epidemiology, Cross Infection microbiology
- Abstract
Background: Clostridioides difficile is a Gram-positive anaerobic bacterium, which causes Clostridioides difficile infection (CDI). It has been recognised as a leading cause of healthcare-associated infections and a considerable threat to public health globally. This systematic literature review (SLR) summarises the current evidence on the epidemiology and clinical burden of CDI., Methods: A SLR was conducted to identify CDI and recurrent CDI (rCDI) epidemiology studies, to evaluate patient and disease characteristics, incidence rates, epidemiological findings and risk factors. Embase, MEDLINE and the Cochrane Library databases were searched for English articles from 2009 to 2019. Included territories were the United Kingdom, France, Germany, Italy, Spain, Poland, US, Canada, Australia, Japan and China., Results: Of 11,243 studies identified, 165 fulfilled the selection criteria. An additional 20 studies were identified through targeted review of grey literature. The most widely reported findings were incidence and risk factors for CDI and rCDI. Among key studies reporting both healthcare-associated (HA-CDI) and community-associated CDI (CA-CDI) incidence rates for each country of interest, incidence rates per 10,000 patient days in the US were 8.00 and 2.00 for HA-CDI and CA-CDI, respectively. The highest incidence in Europe was reported in Poland (HA-CDI: 6.18 per 10,000 patient days, CA-CDI: 1.4 per 10,000 patient days), the lowest from the UK, at 1.99 per 10,000 patient days and 0.56 per 10,000 patient days for HA-CDI and CA-CDI, respectively. No clear trend for incidence over time emerged, with most countries reporting stable rates but some either a decrease or increase. Rates of recurrent CDI varied based on geographical setting. The rate of recurrence was lower in community-associated disease compared to healthcare-associated disease. Independent CDI risk factors identified common to both initial CDI and recurrent CDI included increasing age, antibiotic use, recent hospitalisation, and proton pump inhibitor (PPI) use. In addition, leukocyte count, length of hospital stays, and Charlson comorbidity index score featured as statistically significant risk factors for recurrent CDI, but these are not reported among the most common statistically significant risk factors for initial CDI., Conclusions: Despite considerable heterogeneity, evidence suggests substantial incidence of recurrent and primary CDI, even after considerable efforts in the last decade.
- Published
- 2021
- Full Text
- View/download PDF
39. Psychometric evaluation of the Nocturia Sleep Quality Scale based on data from a prospective observational study.
- Author
-
Williams V, Qin S, Romano CD, Lewis S, Williams N, Yarr S, Juul KV, and Andersson FL
- Subjects
- Humans, Prospective Studies, Psychometrics, Quality of Life, Reproducibility of Results, Sleep, Surveys and Questionnaires, Nocturia
- Abstract
Study Objectives: The Nocturia Sleep Quality Scale (NSQS), a novel patient-reported outcomes measure, was developed to assess the impact of sleep disturbance from nocturia. The objective of this study was to assess the psychometric properties of the NSQS, including its structure, reliability, and validity., Methods: Data were collected in the context of a web-based, prospective, longitudinal, observational study. Participants with nocturia were randomized 1:1 to either a group that received sleep hygiene instructions, including instructions to limit liquids at nighttime and empty bladder prior to bedtime, or one that did not receive sleep instructions. All participants were asked to provide responses to the web-based questionnaires from day 1 to day 10. Psychometric analyses, aligned with current regulatory guidance, were conducted to evaluate the daily scores and 3-day average scores of NSQS items and potential composites. Item-level analyses were conducted first, followed by composite-level analyses., Results: The NSQS items and supporting measures demonstrated very slight improvement in patient-perceived sleep disturbance from nocturia over the course of the study. NSQS test-retest reliabilities were generally satisfactory. Correlations between NSQS items and related patient-reported measures tended to support the construct validity of the NSQS, and the known-groups analyses supplied evidence of its discriminating ability. NSQS responsiveness statistics were small., Conclusions: The NSQS is a reliable and valid measure of the impact of nocturia on patients' sleep. The present analyses lay the psychometric groundwork for the use of the NSQS in future clinical trials to support product approval and labeling claims., (© 2021 American Academy of Sleep Medicine.)
- Published
- 2021
- Full Text
- View/download PDF
40. Achieving clinically meaningful quality of life benefits in nocturia takes time: Results from a long-term, multicenter phase 3 study of desmopressin in Japanese patients.
- Author
-
Juul KV, Andersson FL, and Yamaguchi O
- Subjects
- Deamino Arginine Vasopressin administration & dosage, Female, Humans, Japan, Male, Middle Aged, Nocturia psychology, Surveys and Questionnaires, Time Factors, Treatment Outcome, Urological Agents administration & dosage, Deamino Arginine Vasopressin therapeutic use, Nocturia drug therapy, Quality of Life, Urological Agents therapeutic use
- Abstract
Objectives: To investigate the long-term efficacy, quality of life (QoL), and safety of desmopressin orally disintegrating tablets (ODTs) in Japanese patients with nocturia., Methods: A long-term, multicenter phase 3 study was conducted that enrolled Japanese male and female patients with nocturia (NCT03051009). Male patients received desmopressin 25- or 50-μg ODTs, and female patients received desmopressin 25-μg ODTs for up to 1 year. The primary endpoint was safety. Secondary endpoints included change from baseline in number of nocturnal voids, time to first awakening to void, and QoL assessments (nocturia-specific zQoL [N-QoL], Insomnia Severity Index [ISI], and Hsu bother score)., Results: Overall, 503 patients were enrolled. Reductions from baseline in mean number of nocturnal voids were observed in all treatment groups from week 1 (-0.62 to -1.00), with improvements continuing through week 52 (-1.39 to -1.71). Changes from baseline above or approximating a clinically meaningful improvement were seen by week 52 in the disease-specific N-QoL total score (improved by 11.5-22.6), ISI (improved by -3.9 to -7.1), and Hsu bother scores (improved by -1.5 to -2.0). Adverse events (AEs) were reported in 54.9% of desmopressin-treated patients. Most AEs were mild or moderate in severity., Conclusions: Desmopressin ODTs (25 and 50 μg) demonstrated long-term efficacy, improved QoL, and were well tolerated in Japanese male and female patients with nocturia treated for up to 1 year. Clinically meaningful improvements in patients' QoL, assessed by N-QoL, sleep quality, and bother, occur later than objective symptom improvements, such as voids., (© 2020 John Wiley & Sons Australia, Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
41. Assessing the burden of nocturia in the workplace: the associations between nocturnal voiding, subjective well-being, work engagement and productivity.
- Author
-
Hafner M, Andersson FL, Burtea T, van Stolk C, Whitmore M, Yerushalmi E, and Troxel WM
- Subjects
- Absenteeism, Adolescent, Adult, Aged, Body Mass Index, Cross-Sectional Studies, Employee Performance Appraisal, Female, Health Behavior, Health Status, Humans, Male, Mental Health, Middle Aged, Socioeconomic Factors, Young Adult, Efficiency, Nocturia epidemiology, Sleep Initiation and Maintenance Disorders epidemiology, Work Engagement, Workplace statistics & numerical data
- Abstract
Aims: Nocturia (getting up at night to urinate, where each urination being followed by sleep or intention to sleep) is a bothersome symptom with potentially negative consequences for individual health and daytime functioning. This study assessed the burden of nocturia in the workplace by investigating associations between nocturia and subjective well-being (SWB), work engagement and productivity. Methods: Using large-scale international workplace survey data, the associations between nocturia, SWB, work engagement (Utrecht Work Engagement Scale, UWES-9) and productivity (Work Productivity and Activity Impairment, WPAI) were assessed. Bivariate and multivariate regression analysis was used with adjustment for a large set of confounding factors, including sleep duration and sleep quality. Results: Across a study sample of 92,129 observations, aged 18-70, an average of 10% of the survey population reported ≥2 nocturnal voids (generally considered clinically significant nocturia), with prevalence of nocturia increasing with age. Individuals with nocturia reported a 35.7% ( p < .001) higher relative sleep disturbance score and were 10.5 percentage points (pp) ( p < .001) more likely to report short sleep. Adjusted for covariates, nocturia was associated with a 3.5% ( p < .001) lower relative SWB score and a 2% ( p < .001) lower relative UWES-9 work engagement score. Nocturia was associated with a 3.9 pp ( p < .001) higher work impairment due to absenteeism and presenteeism (WPAI). Adjusting additionally for sleep disturbance and sleep duration reduced the magnitude of the estimated effects, suggesting a key role for poor sleep in explaining the relationship between nocturia and the outcomes (SWB, UWES-9, WPAI) assessed. Conclusions: A key contribution of this study is the assessment of the association between nocturia and a range of work performance outcomes in a sizeable study using validated instruments to measure work engagement and productivity. The study highlights the importance of taking sleep into account when assessing the relationship between nocturia and associated outcomes.
- Published
- 2020
- Full Text
- View/download PDF
42. Impact of nocturia on patients' health-related quality of life and healthcare resource utilisation compared with OAB and BPH: Results from an observational survey in European and American patients.
- Author
-
Zeng VY, Milligan G, Piercy J, Anderson P, and Andersson FL
- Abstract
Objective: To evaluate the impact of nocturia on patients' quality of life and healthcare resource utilisation (HRU) compared with overactive bladder (OAB) and benign prostatic hyperplasia (BPH)., Methods: Data were drawn from a multinational (France, Germany, Spain, UK and US) survey of physician and patient-reported outcomes. The patient groups of interests were those diagnosed with only nocturia, with only OAB, and with only BPH. Health-related quality of life (HRQoL) and productivity measures were derived from the EuroQoL-5D, OAB-q and the Work Productivity and Activity Impairment Questionnaire (WPAI). Measures of HRU included lower urinary tract symptoms (LUTS)-relevant surgeries, hospitalisations, current use of pads and related physician visits. Bivariate and multivariate regression analyses were used to evaluate associations between HRQoL/HRU/Productivity and nocturia status. Multivariate analysis was used to address any potential confounding factors among the groups, ie age, gender, body mass index (BMI), ethnicity and comorbidities., Results: A total of 3552 patients were identified including 358 nocturia patients, 1415 OAB patients and 1779 BPH patients. The mean age of the nocturia patients was 61.2 years with a mean BMI of 27.3. About 60.6% were women, 87.2% were Caucasian, and their most common comorbidities included depression, hypertension and diabetes. In terms of impact, nocturia patients were significantly worse off than OAB patients in their HRQoL. There was no significant difference regarding HRU and productivity measurement. Nocturia patients also presented with significantly worse HRQoL and lower productivity compared with BPH patients. Nocturia patients also had more physician visits., Conclusions: Nocturia should be emphasised as a standalone LUTS disease with substantial patient impact. Compared with OAB and/or BPH, nocturia patients presented with a significant reduction on patients' quality of life, reduced work productivity and increased utilisation of healthcare resources., (© 2019 The Authors. International Journal of Clinical Practice published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
43. Development of the Nocturia Sleep Quality Scale: a patient-reported outcome measure of sleep impact related to nocturia.
- Author
-
Romano CD, Lewis S, Barrett A, Andersson FL, Williams V, Ancoli-Israel S, and Roth T
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Nocturia complications, Qualitative Research, Quality of Life, Sleep Wake Disorders etiology, Nocturia psychology, Patient Reported Outcome Measures, Sleep Wake Disorders psychology
- Abstract
Background/objective: Nocturia's impact on sleep causes significant burden for patients. This study aimed to develop a novel patient-reported outcome (PRO) measure, the Nocturia Sleep Quality Scale (NSQS), for the assessment of the impact of nocturia (defined as ≥2 nocturnal voids/night) on sleep., Methods: Sleep-related concepts were identified through a targeted literature review, after which in-depth concept elicitation interviews with patients with a clinical diagnosis of nocturia were conducted. Draft items were generated to address concepts identified as important, meaningful, and relevant. Items were further refined through three iterative sets of cognitive debriefing interviews to optimize instructions, question wording, and response options. Two sleep research experts also provided input., Results: The literature review and data from 18 concept elicitation interviews provided the basis for a comprehensive set of concepts. Constant comparative analysis was used to identify themes and support item development. The draft questionnaire consisted of 14 items with item-specific response scales. Wording and scaling of the items was optimized based on feedback from the 22 cognitive debriefing interviews and expert input. The results confirmed the completeness and relevance of the NSQS, providing support for the content validity and ability of items to reflect patient perception of nocturia-related sleep impacts., Conclusions: The 6-item NSQS assesses the impact of nocturia on sleep by evaluating nighttime awakenings, sleep quantity, and sleep quality. The NSQS is self-administered and is intended to assess change in nocturia's impact on sleep after treatment in a standardized manner. Psychometric evaluation is under way to describe key measurement properties., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
44. Nocturia is more bothersome than daytime LUTS: Results from an Observational, Real-life Practice Database including 8659 European and American LUTS patients.
- Author
-
Everaert K, Anderson P, Wood R, Andersson FL, and Holm-Larsen T
- Subjects
- Aged, Databases, Factual, Female, France, Germany, Humans, Male, Medical Records, Middle Aged, Prostatic Hyperplasia complications, Quality of Life, Sleep, Sleep Initiation and Maintenance Disorders etiology, Sleep Initiation and Maintenance Disorders psychology, Spain, Surveys and Questionnaires, United States, Urinary Bladder, Overactive complications, Fatigue etiology, Lower Urinary Tract Symptoms complications, Nocturia etiology, Nocturia psychology
- Abstract
Purpose: Lower urinary tract symptoms (LUTS) encompass several diagnoses, including overactive bladder (OAB) and benign prostatic hyperplasia (BPH). Nocturia is a standalone symptom, but also included in OAB and BPH. Current discussion addresses whether the overlap of the diagnoses is too broad, leading to misdiagnosis. This study explored the differences in level, causes and consequences for patients with a diagnosis of daytime LUTS compared with a diagnosis of nocturia, and discussed whether people are being treated for the symptoms that truly bother them the most., Patients and Methods: Data were drawn from a survey of physicians and patients in France, Germany, Spain, UK and USA. Physicians filled out patient record forms (PRFs) for patients with LUTS diagnosis. The patients completed the patient self-completion form (PSC). Three PRO questionnaires were included; the OAB-q SF, NI-Diary and WPAI. Patients were grouped based on the diagnoses assigned to them by their physicians in a real-life setting., Results: Eight thousand seven hundred and thirty eight patients had a LUTS diagnosis and 5335 completed a PSC. Patients diagnosed with night-time symptoms were significantly more bothered by their LUTS than only daytime LUTS patients (all questionnaires P < .0001). Patients with nocturia reported being tired "always" or "usually" more often than patients with daytime problems only (P < .0001). Only 13% of patients with nocturia had an initial sleep period of more than 2-3 hours., Conclusion: In this population of real-life patients, those with a diagnosis of nocturia reported significantly higher impact on their quality of life than patients with a diagnosis of daytime LUTS only. The underlying causes of bother were related to sleep problems. It is essential that nocturia is understood, treated and monitored as a distinct problem from OAB and BPH, to ensure that patients are treated for their main symptom., (© 2018 The Authors. International Journal of Clinical Practice Published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
45. Patients' Lived Experiences of Nocturia: A Qualitative Study of the Evening, the Night, and the Next Day.
- Author
-
Trigg A, Andersson FL, Aldhouse NVJ, Bliwise DL, and Kitchen H
- Subjects
- Adaptation, Psychological, Adult, Age Factors, Aged, Aged, 80 and over, Female, Humans, Interviews as Topic, Male, Middle Aged, Nocturia therapy, Qualitative Research, Quality of Life, Sleep, Socioeconomic Factors, United States, Nocturia psychology
- Abstract
Background: Nocturia, waking to urinate two or more times during the night, is a chronic condition associated with significant patient burden due to sleep disruption. This study aimed to explore the lived experiences of patients with nocturia in terms of the disruption to their lives during the night and day., Methods: Adult patients in the US diagnosed with nocturia were recruited for face-to-face qualitative interviews. Thematic analysis of patients' narratives, taking a phenomenological interpretative approach, summarised their experiences throughout the night and day, including any apparent contrasts between patients., Results: Twenty patients (10 male, 10 female) aged between 39 and 80 years, averaging three night-time voids, were interviewed. Analysis revealed that nocturia has a substantial impact on sleep quality and quantity, with the frequency of night-time voids a key driver of this. In addition to night-time phenomena, patients faced various difficulties the next day, including day-time tiredness, lack of energy and concerns related to emotional wellbeing, social functioning and cognitive functioning. All of these limited patients' capacity to work, perform daily activities or fulfil role responsibilities. Patients' lifestyles influenced experience, where younger patients in employment more readily emphasised the day-time physical and psychosocial burdens. Patients employed coping behaviours in an attempt to lessen the severity of nocturia and its impact, which were both physician-led and self-taught., Conclusions: While the symptom of nocturia only occurs during the night, the impact is longer lasting, affecting functioning and wellbeing throughout the following day. Patients' circumstances can affect the extent of their burden; recognising this can improve effective delivery of patient-centred care.
- Published
- 2017
- Full Text
- View/download PDF
46. Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK.
- Author
-
Weidlich D, Andersson FL, Oelke M, Drake MJ, Jonasson AF, and Guest JF
- Subjects
- Absenteeism, Accidental Falls economics, Algorithms, Cost of Illness, Europe epidemiology, Health Expenditures statistics & numerical data, Health Services economics, Health Services statistics & numerical data, Humans, Male, Models, Econometric, Nocturia epidemiology, Prevalence, Nocturia economics
- Abstract
Objective: Our aim was to estimate the prevalence-based cost of illness imposed by nocturia (≥2 nocturnal voids per night) in Germany, Sweden, and the UK in an average year., Methods: Information obtained from a systematic review of published literature and clinicians was used to construct an algorithm depicting the management of nocturia in these three countries. This enabled an estimation of (1) annual levels of healthcare resource use, (2) annual cost of healthcare resource use, and (3) annual societal cost arising from presenteeism and absenteeism attributable to nocturia in each country., Results: In an average year, there are an estimated 12.5, 1.2, and 8.6 million patients ≥20 years of age with nocturia in Germany, Sweden, and the UK, respectively. In an average year in each country, respectively, these patients were estimated to have 13.8, 1.4, and 10.0 million visits to a family practitioner or specialist, ~91,000, 9000, and 63,000 hospital admissions attributable to nocturia and 216,000, 19,000, and 130,000 subjects were estimated to incur a fracture resulting from nocturia. The annual direct cost of healthcare resource use attributable to managing nocturia was estimated to be approximately €2.32 billion in Germany, 5.11 billion kr (€0.54 billion) in Sweden, and £1.35 billion (€1.77 billion) in the UK. The annual indirect societal cost arising from both presenteeism and absenteeism was estimated to be approximately €20.76 billion in Germany and 19.65 billion kr (€2.10 billion) in Sweden. In addition, in the UK, the annual indirect cost due to absenteeism was an estimated £4.32 billion (€5.64 billion)., Conclusions: Nocturia appears to impose a substantial socioeconomic burden in all three countries. Clinical and economic benefits could accrue from an increased awareness of the impact that nocturia imposes on patients, health services, and society as a whole.
- Published
- 2017
- Full Text
- View/download PDF
47. Nocturia Work Productivity and Activity Impairment Compared with Other Common Chronic Diseases.
- Author
-
Miller PS, Hill H, and Andersson FL
- Subjects
- Chronic Disease, Efficiency, Humans, Quality of Life, Sleep Deprivation etiology, Sleep Initiation and Maintenance Disorders etiology, Nocturia complications, Sleep Deprivation epidemiology, Sleep Initiation and Maintenance Disorders epidemiology
- Abstract
Objectives: The International Continence Society defines nocturia as the need to void one or more times during the night, with each of the voids preceded and followed by sleep. The chronic sleep disturbance and sleep deprivation experienced by patients with nocturia affects quality of life, compromising both mental and physical well-being. This paper aims to characterise the burden of nocturia by comparing published data from patients with nocturia with data from patients with any of 12 other common chronic conditions, specifically focusing on its impact on work productivity and activity impairment, as measured by the instrument of the same name (WPAI)., Methods: A systematic literature review of multiple data sources identified evaluable studies for inclusion in the analysis. Study eligibility criteria included use of the WPAI instrument in patients with one of a predefined list of chronic conditions. We assessed the quality of each included study using the Newcastle-Ottawa scale and extracted basic study information, work and activity impairment data. To assess how work and activity impairment from nocturia compares with impairment from other common chronic diseases, we conducted two data syntheses (pooled and unpooled)., Results: The number of evaluable studies and the range of overall work productivity impairment reported, respectively, were as follows: nocturia (3; 14-39 %), overactive bladder (5; 11-41 %), irritable bowel syndrome/constipation (14; 21-51 %), gastroesophageal reflux disease (GERD) (13; 6-42 %), asthma/allergies (11; 6-40 %), chronic obstructive pulmonary disease (COPD) (7; 19-42 %), sleep problems (3; 12-37 %), arthritis (13; 21-69 %), pain (9; 29-64 %), depression (4; 15-43 %) and gout (2; 20-37 %)., Conclusions: The overall work productivity impairment as a result of nocturia is substantial and was found to be similar to impairment observed as a result of several other more frequently researched common chronic diseases. Greater awareness of the burden of nocturia, a highly bothersome and prevalent condition, will help policy makers and healthcare decision makers provide appropriate management of nocturia.
- Published
- 2016
- Full Text
- View/download PDF
48. The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study.
- Author
-
Brüggenjürgen B, Rossnagel K, Roll S, Andersson FL, Selim D, Müller-Nordhorn J, Nolte CH, Jungehülsing GJ, Villringer A, and Willich SN
- Subjects
- Acute Disease, Aged, Aged, 80 and over, Atrial Fibrillation economics, Berlin, Cost-Benefit Analysis, Demography, Female, Health Resources economics, Hospitals, Urban statistics & numerical data, Humans, Male, Middle Aged, Risk Assessment, Risk Factors, Social Class, Stroke etiology, Surveys and Questionnaires, Atrial Fibrillation complications, Cost of Illness, Health Resources statistics & numerical data, Hospital Costs statistics & numerical data, Hospitals, Urban economics, Stroke economics
- Abstract
Objectives: Atrial fibrillation (AF) is an important risk factor for stroke. The primary purpose of this study was to determine the resource use for patients admitted to hospital with acute stroke and to calculate stroke-related direct costs, stratifying the results according to the presence of AF as a risk factor., Methods: Data from 558 consecutive patients hospitalized with confirmed acute stroke between August 2000 and July 2001 were analyzed as part of the Berlin Acute Stroke Study. Sociodemographic variables were assessed by direct interview, while hospital data were derived from patient medical records. Patients or their carers completed a follow-up questionnaire about resource utilization and absenteeism from work during the 12-month period after hospital admission., Results: Out of the 367 patients with follow-up data and ECG findings, 71 (19%) had AF. Patients with AF were generally older, more likely to be female, and had more severe strokes compared with those without AF. Mean direct costs per patient were significantly higher in those with AF-related strokes (EURO 11,799 vs EURO 8817 for non-AF-related strokes; P < 0.001). After adjustment for confounding factors, direct costs were comparable in the two groups, except for acute hospitalization costs, which remained significantly higher in the group with AF (P < 0.05)., Conclusion: Medical care for stroke patients with AF is associated with higher costs compared with those without AF; this is explained mainly by confounding factors and driven essentially by a significant difference in acute hospitalization costs.
- Published
- 2007
- Full Text
- View/download PDF
49. Hospital use for COPD patients during the last few years of their life.
- Author
-
Andersson FL, Svensson K, and Gerhardsson de Verdier M
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Length of Stay, Male, Palliative Care statistics & numerical data, Pulmonary Disease, Chronic Obstructive mortality, Sweden epidemiology, Hospitalization statistics & numerical data, Pulmonary Disease, Chronic Obstructive therapy
- Abstract
Little is known about what happens to COPD patients during their final years of life, in particular in terms of hospital use. We linked the Swedish Mortality and Inpatient Registers to examine this research question during the period 1987-2000. In year 2000, 2331 fatalities were diagnosed with COPD as the underlying cause of death. About 3% of individuals had not been admitted to hospital at all prior to their death, whereas 15% had never been admitted for COPD (but for other reasons). More than 68% of all COPD admissions and 74% of all days in hospital occurred in the 3.5 years before death, indicating longer stays closer to death. The last 6 months of life accounted for 22% and 28% of all COPD admissions and days, respectively. Other causes accounted for nearly 50% of all admissions, with a more limited increase during the final years. In conclusion, there is a very variable hospital use among these COPD patients. Use increases almost exponentially as the end approaches. Finally, COPD patients often have a number of concomittant diseases which may affect diagnosis and healthcare resource use. The economic and policy implications of these main findings need to be further examined.
- Published
- 2006
- Full Text
- View/download PDF
50. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
- Author
-
McMurray JJ, Andersson FL, Stewart S, Svensson K, Solal AC, Dietz R, Vanhaecke J, van Veldhuisen DJ, Ostergren J, Granger CB, Yusuf S, Pfeffer MA, and Swedberg K
- Subjects
- Angiotensin II Type 1 Receptor Blockers therapeutic use, Benzimidazoles therapeutic use, Biphenyl Compounds, Cardiac Pacing, Artificial statistics & numerical data, Cost-Benefit Analysis, Drug Costs, Heart Failure economics, Heart Failure mortality, Hospital Costs, Hospitalization statistics & numerical data, Humans, Risk Factors, Survival Analysis, Tetrazoles therapeutic use, Thoracic Surgical Procedures statistics & numerical data, Angiotensin II Type 1 Receptor Blockers economics, Benzimidazoles economics, Heart Failure drug therapy, Tetrazoles economics
- Abstract
Aims: More treatments are needed to improve clinical outcomes in chronic heart failure (HF). It is, however, important that treatments for a condition as common as HF are affordable. We have carried out a prospective economic analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme., Methods and Results: Patients with NYHA class II-IV HF and LVEF < or =0.40 were randomized to CHARM-Alternative if intolerant of an ACE-inhibitor or to CHARM-Added if taking an ACE-inhibitor. Patients with a LVEF >0.40 were randomized in CHARM-Preserved. Each trial compared the effect of candesartan to placebo on the primary outcome of cardiovascular death or HF hospitalization. Detailed information was prospectively collected on hospital admissions, procedures/operations and drugs. A cost-consequence analysis was performed for France, Germany and the UK for CHARM-Overall and a cost-effectiveness analysis for the low LVEF trials. The cost of candesartan was substantially offset by a reduction in hospital admissions, especially for HF. In the cost-consequence analysis, candesartan was cost-saving in most scenarios for CHARM-Alternative and Added but the marginal annual net cost per patient was upto 372 euros per year in CHARM-Preserved, in which candesartan did not reduce the primary outcome significantly. In the cost-effectiveness analysis of patients with a LVEF < or = 0.40, candesartan was cost-saving in some scenarios and in the others the maximum cost per life year gained was 3881 euros., Conclusion: Candesartan improves functional class, reduces the risk of hospital admission, and increases survival in patients with a HF and a LVEF < or =0.40 at an acceptable cost.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.